AstraZeneca Concentrates On Collaborations In China
This article was originally published in PharmAsia News
AstraZeneca may not be China's number one MNC pharmaceutical in sales, but its prescription drug revenue has consistently topped the chart for years. This success stems from the various strategies adopted by AstraZeneca China over the past three years that emphasized collaboration. In 2006, the firm dismantled its OTC sales team and worked with local distribution channels to push its drugs. It also pioneered being the first MNC agent representing other companies' pharmaceutical products in China. In the process, the corporation helps to raise domestic enterprises' profile in the worldwide value chain as well as introduce many key global products into China. Drugs brought in include those against major diseases listed in the local medical insurance catalog and products with big potential market. (Click here for more - Chinese Language)
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.